Normal
Business development and corporate deals

ImmuPharma entered into a corporate deal with Cephalon Inc. in 2008, for the worldwide rights of our lead drug candidate for the treatment of Lupus, Lupuzor™ in a $500m plus royalties deal. In late 2011, ImmuPharma regained the rights due to the acquisition of Cephalon by Teva Pharmaceutical Industries. We are now pursuing discussions with other companies for the licensing of Lupuzor™ while also exploring the option of retaining the rights until commercialisation.

ImmuPharma is interested in corporate partnerships for its development assets. Collaborations are core to our strategy and we welcome contacts from other companies interested in partnering with us. Please feel free to contact us at business_development@immupharma.com